Literature DB >> 25229938

Resistance to therapy in acute promyelocytic leukemia.

Jacqueline Lehmann-Che1, Cecile Bally, Hugues de Thé.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25229938     DOI： 10.1056/NEJMc1409040

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  22 in total

1.  FLT3-ITD impedes retinoic acid, but not arsenic, responses in murine acute promyelocytic leukemias.

Authors:  Cécile Esnault; Ramy Rahmé; Kim L Rice; Caroline Berthier; Coline Gaillard; Samuel Quentin; Anne-Lise Maubert; Scott Kogan; Hugues de Thé
Journal:  Blood       Date:  2019-01-23       Impact factor: 22.113

Review 2.  Integration of hypoxic HIF-α signaling in blood cancers.

Authors:  L Schito; S Rey; M Konopleva
Journal:  Oncogene       Date:  2017-05-22       Impact factor: 9.867

Review 3.  Secondary mutations as mediators of resistance to targeted therapy in leukemia.

Authors:  Naval Daver; Jorge Cortes; Farhad Ravandi; Keyur P Patel; Jan A Burger; Marina Konopleva; Hagop Kantarjian
Journal:  Blood       Date:  2015-03-20       Impact factor: 22.113

Review 4.  Predicting Chemotherapy Resistance in AML.

Authors:  Cecilia C S Yeung; Jerald Radich
Journal:  Curr Hematol Malig Rep       Date:  2017-12       Impact factor: 3.952

5.  PRMT5-mediated RNF4 methylation promotes therapeutic resistance of APL cells to As2O3 by stabilizing oncoprotein PML-RARα.

Authors:  Xinping Huang; Yongfeng Yang; Dan Zhu; Yan Zhao; Min Wei; Ke Li; Hong-Hu Zhu; Xiaofeng Zheng
Journal:  Cell Mol Life Sci       Date:  2022-05-27       Impact factor: 9.261

6.  Hyperthermia Selectively Destabilizes Oncogenic Fusion Proteins.

Authors:  Yasen Maimaitiyiming; Qian Qian Wang; Chang Yang; Yasumitsu Ogra; Yinjun Lou; Clayton A Smith; Liaqat Hussain; Yi Ming Shao; Jiebo Lin; Jinfeng Liu; Lingfang Wang; Yong Zhu; Haiyan Lou; Yuan Huang; Xiaoxia Li; Kao-Jung Chang; Hao Chen; Hongyan Li; Ying Huang; Eric Tse; Jie Sun; Na Bu; Shih-Hwa Chiou; Yan Fang Zhang; Hao Ying Hua; Li Ya Ma; Ping Huang; Ming Hua Ge; Feng-Lin Cao; Xiaodong Cheng; Hongzhe Sun; Jin Zhou; Vasilis Vasliou; Pengfei Xu; Jie Jin; Mikael Bjorklund; Hong-Hu Zhu; Chih-Hung Hsu; Hua Naranmandura
Journal:  Blood Cancer Discov       Date:  2021-05-11

7.  Targeting pseudokinase TRIB3 brings about a new therapeutic option for acute promyelocytic leukemia.

Authors:  Ke Li; Feng Wang; Zhuo-Wei Hu
Journal:  Mol Cell Oncol       Date:  2017-06-16

Review 8.  p53 as an Effector or Inhibitor of Therapy Response.

Authors:  Julien Ablain; Brigitte Poirot; Cécile Esnault; Jacqueline Lehmann-Che; Hugues de Thé
Journal:  Cold Spring Harb Perspect Med       Date:  2015-12-04       Impact factor: 6.915

9.  Actinomycin D Targets NPM1c-Primed Mitochondria to Restore PML-Driven Senescence in AML Therapy.

Authors:  Domitille Rérolle; Caroline Berthier; Rita Hleihel; Takashi Sakamoto; Hsin-Chieh Wu; Samuel Quentin; Shirine Benhenda; Claudia Morganti; Chengchen Wu; Lidio Conte; Sylvie Rimsky; Marie Sebert; Emmanuelle Clappier; Sylvie Souquere; Stéphanie Gachet; Jean Soulier; Sylvère Durand; Jennifer J Trowbridge; Paule Bénit; Pierre Rustin; Hiba El Hajj; Emmanuel Raffoux; Lionel Ades; Raphael Itzykson; Hervé Dombret; Pierre Fenaux; Olivier Espeli; Guido Kroemer; Lorenzo Brunetti; Tak W Mak; Valérie Lallemand-Breitenbach; Ali Bazarbachi; Brunangelo Falini; Keisuke Ito; Maria Paola Martelli; Hugues de Thé
Journal:  Cancer Discov       Date:  2021-12-01       Impact factor: 38.272

10.  Rationale and efficacy of proteasome inhibitor combined with arsenic trioxide in the treatment of acute promyelocytic leukemia.

Authors:  S Ganesan; A A Alex; E Chendamarai; N Balasundaram; H K Palani; S David; U Kulkarni; M Aiyaz; R Mugasimangalam; A Korula; A Abraham; A Srivastava; R A Padua; C Chomienne; B George; P Balasubramanian; V Mathews
Journal:  Leukemia       Date:  2016-08-18       Impact factor: 11.528
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.